Published in World J Gastroenterol on May 07, 2006
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep (1998) 12.78
Interferons and their actions. Annu Rev Biochem (1987) 8.36
Therapy of hepatitis C: overview. Hepatology (1997) 1.61
Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology (1997) 1.54
Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet (1991) 1.45
Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen. J Gastroenterol (2001) 1.44
A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology (1993) 1.11
Immunogenicity of interferon beta: differences among products. J Neurol (2004) 1.05
Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol (2004) 0.98
Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens. J Hepatol (2003) 0.94
Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology (2000) 0.92
Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C. Aliment Pharmacol Ther (2000) 0.90
The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C. Hepatogastroenterology (2003) 0.90
Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci (1999) 0.88
Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients. J Viral Hepat (2004) 0.88
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol (1998) 0.86
[beta-Interferon therapy of chronic hepatitis HCV+, 1b genotype]. Recenti Prog Med (1998) 0.85
Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol (2002) 0.84
A pilot study of beta-interferon for treatment of patients with chronic hepatitis B who failed to respond to alpha-interferon. J Hepatol (2002) 0.84
Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C. Med Sci Monit (2001) 0.83
A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C. Liver (2000) 0.83
Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needle-stick. J Clin Gastroenterol (1999) 0.82
Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy. J Hepatol (2001) 0.82
Combined antiviral options for the treatment of chronic hepatitis C. Antiviral Res (2003) 0.82
Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon. Am J Gastroenterol (1998) 0.81
Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C. J Viral Hepat (1999) 0.81
Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol (2005) 0.81
High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group. Dig Dis Sci (2000) 0.81
Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology (1994) 0.81
Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators. Scand J Gastroenterol (1999) 0.80
Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. J Hepatol (2000) 0.80
The efficacy of a herbal medicine (Mao-to) in combination with intravenous natural interferon-beta for patients with chronic hepatitis C, genotype 1b and high viral load: a pilot study. Phytomedicine (2002) 0.80
Tolerance and efficacy of subcutaneous interferon-beta administered for treatment of chronic hepatitis C. J Interferon Cytokine Res (1997) 0.80
Randomized controlled trial of twice-a-day administration of natural interferon beta for chronic hepatitis C. Hepatol Res (2000) 0.79
Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C. Hepatogastroenterology (2003) 0.79
A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus. Hepatogastroenterology (2003) 0.79
Intramuscular beta interferon for chronic hepatitis C: is it worth trying? Ital J Gastroenterol Hepatol (1998) 0.79
Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the treatment of chronic hepatitis C. J Viral Hepat (1995) 0.79
Physicochemical and biologic properties of interferons and their potential uses in drug delivery systems. Crit Rev Ther Drug Carrier Syst (1992) 0.79
Efficacy of early retreatment with interferon beta for relapse in patients with genotype Ib chronic hepatitis C. Hepatol Res (2004) 0.78
Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon. Ital J Gastroenterol Hepatol (1997) 0.78
Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study. Dig Dis Sci (1996) 0.78
Recommendations from the National Institutes of Health consensus development conference statement: management of hepatitis C: 2002. Hepatology (2002) 0.78
Additive therapeutic effects of the liver extract preparation mixture adelavin-9 on interferon-beta treatment for chronic hepatitis C. Hepatogastroenterology (2004) 0.78
Treatment of chronic non-A non-B hepatitis with human interferon beta: a preliminary study. Antiviral Res (1989) 0.78
Interferon-beta treatment of human disease. Curr Opin Biotechnol (1995) 0.77
Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C. J Interferon Cytokine Res (1997) 0.77
[Hepatitis C]. Clin Ter (1996) 0.77
Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C. World J Gastroenterol (2004) 0.76
Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first 2 weeks of IFN-beta treatment are predictive of long-term therapeutic response. J Interferon Cytokine Res (2002) 0.76
Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus. Hepatogastroenterology (2002) 0.76
Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. The TVVH Study Group. J Hepatol (1993) 0.76
Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology (2003) 1.93
Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J Hepatol (2005) 1.93
Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol (2003) 1.86
Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care (2004) 1.42
Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. J Hepatol (2002) 1.07
Liver disease and erythropoietic protoporphyria: a concise review. World J Gastroenterol (2010) 1.06
Autoimmune hepatitis after long-term methotrexate therapy for rheumatoid arthritis. Curr Drug Saf (2011) 0.99
The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology (2005) 0.96
Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis. J Hepatol (2003) 0.90
Drug-induced postinfantile giant cell hepatitis. Hepatology (2010) 0.89
The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Eur J Gastroenterol Hepatol (2004) 0.86
Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann Hepatol (2013) 0.86
Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol (2010) 0.83
Hepatoprotective effects of antioxidants in chronic hepatitis C. World J Gastroenterol (2010) 0.82
Combined antiviral options for the treatment of chronic hepatitis C. Antiviral Res (2003) 0.82
Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. Eur J Gastroenterol Hepatol (2004) 0.82
[Transient elastography (Fibroscan), a new non-invasive method to evaluate hepatic fibrosis]. Med Clin (Barc) (2006) 0.79
Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link. PLoS One (2013) 0.78
Role of tight junctions in hepatitis C virus infection. Rev Esp Enferm Dig (2012) 0.77
Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease. Rev Esp Enferm Dig (2013) 0.76
Tenofovir treatment of the severe acute hepatitis B. Rev Esp Enferm Dig (2013) 0.75
Chronic hepatitis C genotype 2 or 3 short treatment. Hepatology (2008) 0.75
Preliminary evidence of sustained expression of angiopoietin-2 during monocyte differentiation in chronic hepatitis C. Liver Int (2013) 0.75
Extrahepatic conditions associated with primary biliary cirrhosis. Hepatology (2010) 0.75
Safety of methotrexate for inflammatory bowel disease. Dig Liver Dis (2012) 0.75
Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report and a short review of the literature. J Crohns Colitis (2012) 0.75
[Chronic C hepatitis genotype 4]. Med Clin (Barc) (2010) 0.75
Large asymptomatic type III paraesophageal hernia. Rev Esp Enferm Dig (2011) 0.75
High Frequency of Severe Telaprevir-associated Skin Eruptions in Clinical Practice. Acta Derm Venereol (2016) 0.75
Profiles and clinical management of hepatitis C patients in Spain: disHCovery study. Rev Esp Quimioter (2015) 0.75
[Hepatic disease in hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease)]. Med Clin (Barc) (2007) 0.75
Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. Eur J Gastroenterol Hepatol (2015) 0.75
Idiopathic portal hypertension complicated by ischemic hepatitis: the diagnostic importance of hemodynamics and liver biopsy. Rev Esp Enferm Dig (2012) 0.75